IPHYF
Price
$2.06
Change
+$0.75 (+57.25%)
Updated
Aug 11 closing price
Capitalization
197.73M
ISCO
Price
$0.14
Change
+$0.01 (+7.69%)
Updated
Sep 3 closing price
Capitalization
1.12M
Interact to see
Advertisement

IPHYF vs ISCO

Header iconIPHYF vs ISCO Comparison
Open Charts IPHYF vs ISCOBanner chart's image
Innate Pharma
Price$2.06
Change+$0.75 (+57.25%)
Volume$300
Capitalization197.73M
International Stem Cell
Price$0.14
Change+$0.01 (+7.69%)
Volume$7.11K
Capitalization1.12M
IPHYF vs ISCO Comparison Chart in %
Loading...
IPHYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPHYF vs. ISCO commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPHYF is a Hold and ISCO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (IPHYF: $2.06 vs. ISCO: $0.14)
Brand notoriety: IPHYF and ISCO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPHYF: 79% vs. ISCO: 100%
Market capitalization -- IPHYF: $197.73M vs. ISCO: $1.12M
IPHYF [@Biotechnology] is valued at $197.73M. ISCO’s [@Biotechnology] market capitalization is $1.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPHYF’s FA Score shows that 0 FA rating(s) are green whileISCO’s FA Score has 1 green FA rating(s).

  • IPHYF’s FA Score: 0 green, 5 red.
  • ISCO’s FA Score: 1 green, 4 red.
According to our system of comparison, ISCO is a better buy in the long-term than IPHYF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPHYF’s TA Score shows that 3 TA indicator(s) are bullish while ISCO’s TA Score has 1 bullish TA indicator(s).

  • IPHYF’s TA Score: 3 bullish, 3 bearish.
  • ISCO’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, IPHYF is a better buy in the short-term than ISCO.

Price Growth

IPHYF (@Biotechnology) experienced а 0.00% price change this week, while ISCO (@Biotechnology) price change was +6.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IPHYF($198M) has a higher market cap than ISCO($1.12M). ISCO YTD gains are higher at: 72.202 vs. IPHYF (-28.983).
IPHYFISCOIPHYF / ISCO
Capitalization198M1.12M17,663%
EBITDAN/A128K-
Gain YTD-28.98372.202-40%
P/E RatioN/AN/A-
RevenueN/A9.2M-
Total CashN/A920K-
Total DebtN/A3.85M-
FUNDAMENTALS RATINGS
IPHYF vs ISCO: Fundamental Ratings
IPHYF
ISCO
OUTLOOK RATING
1..100
4112
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
3940
P/E GROWTH RATING
1..100
10088
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is significantly better than the same rating for IPHYF (75). This means that ISCO’s stock grew significantly faster than IPHYF’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as IPHYF (100). This means that ISCO’s stock grew similarly to IPHYF’s over the last 12 months.

IPHYF's SMR Rating (95) in the null industry is in the same range as ISCO (100). This means that IPHYF’s stock grew similarly to ISCO’s over the last 12 months.

IPHYF's Price Growth Rating (39) in the null industry is in the same range as ISCO (40). This means that IPHYF’s stock grew similarly to ISCO’s over the last 12 months.

ISCO's P/E Growth Rating (88) in the null industry is in the same range as IPHYF (100). This means that ISCO’s stock grew similarly to IPHYF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPHYFISCO
RSI
ODDS (%)
Bearish Trend 1 day ago
55%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
47%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
40%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
Bearish Trend 25 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IPHYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GASFX28.68N/A
N/A
Hennessy Gas Utility Investor
EEMHX9.39N/A
N/A
MFS Emerging Markets Equity Research R6
PCAOX86.28N/A
N/A
Principal Capital Appreciation R3
MDFSX8.15N/A
N/A
Manning & Napier Disciplined Value S
GSPUX44.26N/A
N/A
Goldman Sachs Large Cap Equity R6

IPHYF and

Correlation & Price change

A.I.dvisor tells us that IPHYF and KNBIF have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPHYF and KNBIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHYF
1D Price
Change %
IPHYF100%
N/A
KNBIF - IPHYF
6%
Poorly correlated
N/A
INNMF - IPHYF
6%
Poorly correlated
-3.21%
OTLC - IPHYF
4%
Poorly correlated
+10.06%
ISCO - IPHYF
1%
Poorly correlated
N/A
LIXT - IPHYF
1%
Poorly correlated
+2.24%
More